Militia Capital Management LLC Invests $2.32 Million in Regeneron Pharmaceuticals, Inc. $REGN

Militia Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,318,000.

Other hedge funds also recently bought and sold shares of the company. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Kemnay Advisory Services Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. Finally, Entrust Financial LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued confidence in the company’s longer-term upside. Benzinga
• Neutral Sentiment: Regeneron also provided an update that its mid-stage POTS study for REGN7544 has wrapped up, but the article does not include enough detail to gauge the readout’s financial or clinical impact yet. TipRanks
• Negative Sentiment: Several firms, including Bronstein, Gewirtz & Grossman, Bernstein Liebhard, Bleichmar Fonti & Auld, Pomerantz, the Schall Law Firm, and others, announced or promoted a class action lawsuit against Regeneron over alleged securities-law violations tied to trial disclosures and the subsequent stock decline, keeping legal risk in focus for investors. PR Newswire

Regeneron Pharmaceuticals Trading Down 3.6%

Shares of Regeneron Pharmaceuticals stock opened at $651.18 on Thursday. The stock has a 50 day moving average of $637.84 and a 200 day moving average of $715.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm has a market capitalization of $68.84 billion, a price-to-earnings ratio of 15.87, a PEG ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the business earned $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. HSBC lowered their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Finally, TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $787.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.